183 related articles for article (PubMed ID: 27384855)
1. [Severe 6-mercaptopurine-induced hematotoxicity in childhood an ALL patient with homozygous NUDT15 missence variants].
Kimura S; Hasegawa D; Yoshimoto Y; Hirabayashi S; Hosoya Y; Yoshihara H; Kumamoto T; Tanaka Y; Manabe A
Rinsho Ketsueki; 2016 Jun; 57(6):748-53. PubMed ID: 27384855
[TBL] [Abstract][Full Text] [Related]
2.
Puangpetch A; Tiyasirichokchai R; Pakakasama S; Wiwattanakul S; Anurathapan U; Hongeng S; Sukasem C
Pharmacogenomics; 2020 Apr; 21(6):403-410. PubMed ID: 32308129
[No Abstract] [Full Text] [Related]
3. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
[TBL] [Abstract][Full Text] [Related]
4. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
5. The influence of
Nguyen ML; Hoang AV; Duong BT; Phung NTN
HGG Adv; 2023 Apr; 4(2):100183. PubMed ID: 36873097
[TBL] [Abstract][Full Text] [Related]
6. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
7. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
[TBL] [Abstract][Full Text] [Related]
8. NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine.
Khaeso K; Komvilaisak P; Chainansamit SO; Nakkam N; Suwannaying K; Kuwatjanakul P; Hikino K; Dornsena A; Kanjanawart S; Laoaroon N; Vannaprasaht S; Taketani T; Tassaneeyakul W
Drug Metab Pharmacokinet; 2022 Apr; 43():100436. PubMed ID: 35016134
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.
Moriyama T; Yang W; Smith C; Pui CH; Evans WE; Relling MV; Bhatia S; Yang JJ
Pharmacogenet Genomics; 2022 Feb; 32(2):60-66. PubMed ID: 34412101
[TBL] [Abstract][Full Text] [Related]
10. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
[TBL] [Abstract][Full Text] [Related]
11. Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants.
Wang DS; Yu CH; Lin CY; Chang YH; Lin KH; Lin DT; Jou ST; Lu MY; Chang HH; Lin SW; Chen HY; Yang YL
Pediatr Res; 2021 Jan; 89(1):217-222. PubMed ID: 32221476
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
Stocco G; Cheok MH; Crews KR; Dervieux T; French D; Pei D; Yang W; Cheng C; Pui CH; Relling MV; Evans WE
Clin Pharmacol Ther; 2009 Feb; 85(2):164-72. PubMed ID: 18685564
[TBL] [Abstract][Full Text] [Related]
13. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
[TBL] [Abstract][Full Text] [Related]
15. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia.
Singh M; Bhatia P; Khera S; Trehan A
Leuk Res; 2017 Nov; 62():17-22. PubMed ID: 28963908
[TBL] [Abstract][Full Text] [Related]
17. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia.
Liang DC; Yang CP; Liu HC; Jaing TH; Chen SH; Hung IJ; Yeh TC; Lin TH; Lai CL; Lai CY; Shih LY
Pharmacogenomics J; 2016 Nov; 16(6):536-539. PubMed ID: 26503813
[TBL] [Abstract][Full Text] [Related]
18. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
19. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.
Yang JJ; Landier W; Yang W; Liu C; Hageman L; Cheng C; Pei D; Chen Y; Crews KR; Kornegay N; Wong FL; Evans WE; Pui CH; Bhatia S; Relling MV
J Clin Oncol; 2015 Apr; 33(11):1235-42. PubMed ID: 25624441
[TBL] [Abstract][Full Text] [Related]
20. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
